Home » Stocks » Emmaus Life Sciences

Emmaus Life Sciences, Inc. (EMMA)

Stock Price: $1.88 USD 0.01 (0.53%)
Updated Jul 15, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 91.13M
Revenue (ttm) 24.10M
Net Income (ttm) -32.89M
Shares Out 48.47M
EPS (ttm) -2.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 15, 2020
Last Price $1.88
Previous Close $1.87
Change ($) 0.01
Change (%) 0.53%
Day's Open 3.07
Day's Range 1.80 - 1.90
Day's Volume 49,995
52-Week Range 0.85 - 9.88

More Stats

Market Cap 91.13M
Enterprise Value 73.70M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 48.47M
Float 29.24M
EPS (basic) -4.34
EPS (diluted) -2.09
FCF / Share -0.15
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 41,217
Short Ratio 0.48
Short % of Float 0.09%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 3.78
PB Ratio n/a
Revenue 24.10M
Operating Income -11.89M
Net Income -32.89M
Free Cash Flow -6.88M
Net Cash 17.42M
Net Cash / Share 0.36
Gross Margin 59.39%
Operating Margin -49.34%
Profit Margin -441.10%
FCF Margin -28.54%
ROA -3.24%
ROE n/a
ROIC -116.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$24.00*
Low
24.0
Current: 1.88
High
24.0
Target: 24.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20182017201620152014201320122011
Revenue1.320.130.090.100.140.130.120.11
Revenue Growth923.74%51%-14.99%-25.91%3.21%13.83%3.23%-
Gross Profit0.490.080.080.100.06-0.01-0.02-0.04
Operating Income-10.24-7.10-3.77-2.65-3.82-4.20-4.81-5.29
Net Income-9.60-7.11-5.94-3.38-2.66-10.91-3.41-8.33
Shares Outstanding0.870.470.110.080.080.06--
Earnings Per Share-11.16-15.12-55.56-39.84-36.00-168.00-2,172.00-5,687.99
Operating Cash Flow-9.04-4.79-2.98-2.16-3.27-3.04-2.34-3.57
Capital Expenditures-0.06-0.13------0.02
Free Cash Flow-9.09-4.92-2.98-2.15-3.27-3.03-2.34-3.59
Cash & Equivalents3.255.610.320.431.241.270.010.07
Total Debt0.590.040.092.771.480.017.404.28
Net Cash / Debt2.665.570.22-2.34-0.241.26-7.39-4.21
Assets5.156.100.510.571.341.400.130.37
Liabilities1.871.551.585.403.103.5613.2011.79
Book Value4.024.55-1.06-4.84-1.76-2.16-13.07-11.42
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Emmaus Life Sciences, Inc.
Country United States
Employees 28
CEO Yutaka Niihara

Stock Information

Ticker Symbol EMMA
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: EMMA

Description

Emmaus Life Sciences, Inc. engages in the discovery, development, and commercialization of treatments and therapies primarily for rare and orphan diseases in the United States and internationally. It provides Endari, which is L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older; NutreStore L-glutamine powder; and AminoPure, a nutritional supplement. The company also develops therapeutic products based on cell sheet technology for the treatment of corneal diseases. In addition, it focuses on developing pharmaceutical-grade L-glutamine oral powder for diverticulosis. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.